Editorial: Osteoporosis and adipokines: the potential for future treatment
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/12501/Tariq-Sundus-2024.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Date
2024Metadata
Show full item recordCitation
Tariq, S., Tariq, S., Baig, M. ve Valjevac, A. (2024). Editorial: Osteoporosis and adipokines: the potential for future treatment. Frontiers in Endocrinology, 15. http://dx.doi.org/10.3389/fendo.2024.1405412Abstract
Osteoporosis is a major health concern, particularly in older people. It is characterized
by decreased bone density and a higher fracture risk. Globally, it affects 35.3% of women
and 12.5% of men (1). Recent studies have concentrated on the role of adipokines in bone
metabolism control and osteoporosis progression. Adipokines are signaling substances
produced by adipose tissue. Leptin, resistin, chemerin, visfatin, and other proteins have
been shown to alter bone metabolism, making them possible targets for future osteoporosis
treatments (2–4).